HC Wainwright Reaffirms “Sell” Rating for Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “sell” rating reiterated by HC Wainwright in a report released on Thursday,Benzinga reports. They presently have a $75.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target points to a potential downside of 29.74% from the company’s previous close.

Other equities analysts also recently issued research reports about the stock. Cantor Fitzgerald raised shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and raised their target price for the company from $152.00 to $167.00 in a research note on Thursday, November 7th. Deutsche Bank Aktiengesellschaft started coverage on shares of Sarepta Therapeutics in a report on Tuesday, February 11th. They issued a “hold” rating and a $136.00 price target for the company. StockNews.com lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. Guggenheim boosted their price target on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $202.00 target price on shares of Sarepta Therapeutics in a report on Monday, January 27th. One research analyst has rated the stock with a sell rating, three have given a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Sarepta Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $173.52.

Sarepta Therapeutics Stock Up 3.6 %

Shares of NASDAQ:SRPT opened at $106.75 on Thursday. The stock’s 50-day moving average price is $115.89 and its two-hundred day moving average price is $122.61. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics has a 12-month low of $101.00 and a 12-month high of $173.25. The firm has a market cap of $10.20 billion, a price-to-earnings ratio of 85.40 and a beta of 0.75.

Insider Transactions at Sarepta Therapeutics

In related news, Director Kathryn Jean Boor sold 1,636 shares of the stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the sale, the director now directly owns 5,880 shares in the company, valued at $738,234. This trade represents a 21.77 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the sale, the director now owns 22,840 shares in the company, valued at $2,851,345.60. This represents a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is owned by insiders.

Institutional Trading of Sarepta Therapeutics

Several hedge funds have recently bought and sold shares of SRPT. GF Fund Management CO. LTD. bought a new position in shares of Sarepta Therapeutics during the 4th quarter worth approximately $244,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Sarepta Therapeutics by 11.6% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 299,301 shares of the biotechnology company’s stock worth $36,392,000 after buying an additional 31,098 shares in the last quarter. Woodline Partners LP acquired a new stake in shares of Sarepta Therapeutics during the fourth quarter worth $5,713,000. Vestal Point Capital LP acquired a new stake in shares of Sarepta Therapeutics during the fourth quarter worth $30,398,000. Finally, Vident Advisory LLC acquired a new stake in shares of Sarepta Therapeutics during the fourth quarter worth $357,000. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.